Bengaluru — On Tuesday, Pfizer said it was reviewing options for its consumer healthcare business, including a full or partial separation of the unit. Pfizer said the consumer healthcare business, which earned about $3.4bn in revenue in 2016, was "distinct enough" from its core business that there was potential for it to be more valuable outside the company. Pfizer’s consumer healthcare business includes brands such as ChapStick. The company’s shares were up about 1% at $36.50 in pre-market trading. The company said any decision related to the options would be made during 2018. Pfizer said it hired Centerview Partners, Guggenheim Securities and Morgan Stanley & Co as financial advisers for the review. Germany’s Merck had hired JP Morgan to sell its consumer health business, Reuters reported last month. Reuters
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.